<DOC>
	<DOCNO>NCT00328926</DOCNO>
	<brief_summary>Sponsor decide discontinue Luveris® United States ( US ) due level customer demand product , due efficacy safety concern .</brief_summary>
	<brief_title>Luveris® ( Lutropin Alfa Injection ) Women With Hypogonadotropic Hypogonadism ( Luteinizing Hormone LH Less Than &lt; 1.2 International Unit Per Liter IU/L )</brief_title>
	<detailed_description>To confirm efficacy 75 IU dose Luveris® compare placebo administer concomitantly follitropin alfa induction clinical pregnancy woman hypogonadotropic hypogonadism profound LH deficiency ( LH &lt; 1.2 IU/L ) , study efficacy low dose ( 25 IU ) Luveris® compare placebo administer concomitantly follitropin alfa induction follicular development woman hypogonadotropic hypogonadism profound LH deficiency ( LH &lt; 1.2 IU/L ) .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<criteria>Be premenopausal , 18 40 year age inclusive day consent Have clinical history hypogonadotropic hypogonadism ( World health organization [ WHO ] Group I type anovulation ) basis congenital acquire hypothalamic pituitary endocrine dysfunction presence qualify screen laboratory Have prior treatment cycle gonadotropins gonadotropin release hormone ( GnRH ) ( gonadotropin naïve ) Have discontinue estrogenprogesterone replacement therapy least one month screen procedure Have primary secondary amenorrhea Have negative progestin challenge test perform Screening Have follow hormonal value centrally analyze fast blood sample , drawn within 6 week initiation treatment : FollicleStimulating Hormone ( FSH ) : le ( &lt; ) 5 international unit per liter ( IU/L ) Leutinizing hormone ( LH ) : &lt; 1.2 IU/L ( second Baseline serum LH level repeat two week initial LH draw ) Prolactin : &lt; 43.3 nanogram per milliliter ( ng/mL ) ( &lt; 1040 milliinternational unit per liter [ mIU/L ] ) Thyroid Stimulating Hormone ( TSH ) : &lt; 6.5 microinternational unit per milliliter ( mcIU/mL ) Free Thyroxin ( T4 ) : 0.81.8 nanogram per deciliter ( ng/dL ) ( 1124 picomole per liter [ pmol/L ] ) Testosterone : &lt; 1.0 ng/mL ( &lt; 3.5 nanomole per liter [ nmol/L ] ) Have endovaginal pelvic ultrasound scan showing ( ) clinically significant uterine abnormality , ( ii ) ovarian tumor cyst , ( iii ) less equal ( = &lt; ) 13 small follicle ( mean diameter = &lt; 10 milliliter [ mm ] ) large section ovary Have normal cervical pap smear within 6 month initial visit Where indicate , normal unchanged compute tomography ( CT ) scan nuclear magnetic resonance ( NMR ) scan hypothalamic pituitary region file Have body mass index ( BMI ) 18.4 31.4 kilogram per square meter ( kg/m^2 ) Be willing able comply protocol duration study Have give write informed consent prior study related procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care Any medical condition judgment investigator may interfere absorption , distribution , metabolism excretion drug Any preexisting medical condition would compromise subject 's ability conceive vivo successfully complete pregnancy Ongoing pregnancy Clinically important systemic disease ( example : insulindependent diabetes mellitus , epilepsy , serious migraine , intermittent purpura , hepatic , renal cardiovascular disease , serious corticoiddependent asthma ) Known infection human immunodeficiency virus ( HIV ) , Hepatitis B C Ovarian enlargement cyst unknown etiology Abnormal gynecological bleeding undetermined origin Previous current hormone dependent tumor Known active substance abuse eat disorder Known central nervous system ( CNS ) Lesions : In case hypogonadotropic hypogonadism ( HH ) secondary CNS lesion treatment Exercise program exceed 10 hour per week Is plan undergo vitro fertilization , intracytoplasmic sperm injection another assist reproductive technology ( ART ) procedure , intrauterine insemination , course study treatment cycle Currently undergo treatment psychotropic medication medication know interfere normal reproductive function ( example : neuroleptic , dopamine antagonist )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Hypogonadotropic Hypogonadism ( LH &lt; 1.2 IU/L )</keyword>
	<keyword>Placebo</keyword>
	<keyword>Luveris® 75 IU</keyword>
	<keyword>Luveris® 25 IU</keyword>
	<keyword>Recombinant human chorionic gonadotropin ( r-hCG )</keyword>
</DOC>